Mirati Therapeutics Stock News

A longer-than-expected regulatory review for the company''s lung cancer drug is weighing on its shares today.

At least two Street firms have cut price targets on Mirati Therapeutics (MRTX) after the company Tuesday said its New Drug Application for its KRAS inhibitor. adagrasib will get a…

A longer-than-expected regulatory review for the company's lung cancer drug is weighing on its shares today.

The FDA has accepted for review Mirati Therapeutics Inc''s (NASDAQ: MRTX ) marketing application seeking approval for adagrasib for non-small cell lung cancer (NSCLC). The application covers NSCLC patients harboring the KRASG12C mutation who have received at least one prior systemic therapy. The Prescription Drug User Fee Action … Full story available on Benzinga.com

Futures Tread Water Ahead Of FOMC Mintues As Russia Forgets To Invade Ukraine The global rally stalled on Wednesday, and U.S. index futures were flat, treading water after a quiet overnight session, ahead of today''s FOMC minutes which some hope will unveil more detail on the Fed''s upcoming rate hike and QT, while also weighing the risks from the Ukraine tensions against inflation and tighter monetary policy. S&P 500 futures were flat and Nasdaq futures were little changed by 7:15 a.m. in New York, trimming earlier gains after NATO Sec. Stoltenberg pushed back on claims of Russian troop withdrawals, adding he is yet to see signs of a de-escalation. Treasury yields, bitcoin, gold and the dollar were also all flat. Oil recovered after the biggest one-day loss this year as worries about potential disruptions to commodity supplies eased. Making a mockery of the Deep State/CIA/CNN which predicted that a Russian invasion would take place today, the Russian defense ministry announced more troops were returning to their bases after maneuvers ended in Crimea, while western officials remained cautious.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

Mirati Therapeutics (MRTX) is trading ~7% lower in the pre-market on Wednesday. Read more about the reason

The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lung cancer (NSCLC). The application covers NSCLC pa

Gainers: HOOKIPA Pharma HOOK +54%. Upstart Holdings UPST +23%

Mirati Therapeutics said Tuesday that U.S. regulators accepted an application for its KRAS-blocking lung cancer drug, but the review time will be longer than hoped.

SAN DIEGO , Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of

Shares of Mirati Therapeutics are down significantly today as a consequence of poor quarterly sales of Amgen''s Lumakras (sotorasib) non-small cell lung cancer treatment.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.